VEDOLIZUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AA33
UNII: 9RV78Q2002

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Integrin alpha-4/beta-7 inhibitor
Primary Target
integrin α4β7

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Pouchitis 3 D019449 ClinicalTrials
Infections 2 D007239 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials
Colitis 2 D003092 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Celiac Disease 2 D002446 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Inflammatory Bowel Diseases 1 D015212 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
Diabetes Mellitus, Type 1 1 D003922 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
18.8
General disorders and administration site conditions
12.16
Injury, poisoning and procedural complications
9.22
Infections and infestations
7.05
Investigations
6.52
Nervous system disorders
5.71
Respiratory, thoracic and mediastinal disorders
5.29
Musculoskeletal and connective tissue disorders
5.24
Vascular disorders
4.78
Immune system disorders
4.29
Skin and subcutaneous tissue disorders
3.98
Cardiac disorders
2.71
Surgical and medical procedures
2.41
Psychiatric disorders
2.11

Cross References

Resources Reference
CAS NUMBER 943609-66-3
ChEMBL CHEMBL1743087
FDA SRS 9RV78Q2002
Guide to Pharmacology 7437
CONTENTS